Reglan (generic: metoclopramide) is used in the treatment of heartburn caused by gastroesophageal reflux. Mounting evidence suggests that the continual use of Reglan may lead to the development of tardive dyskinesia.
UPDATE: 650 Lawsuits Involving Generic Reglan Allowed to Proceed
November 13, 2014 — An appeals court in New Jersey has ruled that hundreds of failure-to-warn lawsuits involving generic Reglan (metoclopramide) are not preempted by federal law. Click here to read more.
Reglan is a dopamine antagonist whose main function is to increase muscle contractions in the upper digestive tract. By doing so, the rate in which food food enters the intestine is increased. However, empirical evidence suggests that those who use Reglan to treat the symptoms of gastroesophageal reflux may be at an increased risk of developing a condition known as tardive dyskinesia.
The reported links between Reglan and tardive dyskinesia garnished the attention of the U.S. Food and Drug Administration (FDA) in 2009. The FDA acknowledged the adverse health effects associated with the medication and ordered the makers of Reglan to add a boxed warning label that emphasized the risk of developing tardive dyskinesia.